D-fraction (Grifola frondosa proteoglucan)
Clinical trialMechanism of Action
Research Notes
Nanba and colleagues demonstrated D-fraction's anti-tumor activity in sarcoma 180-bearing mice (1987–1995), with tumor regression rates of 70–90% in some models. A Phase I/II trial at Memorial Sloan Kettering (Deng et al., 2009) in 34 postmenopausal breast cancer patients showed that D-fraction stimulated NK cell activity and enhanced immunological function without significant adverse effects. Kodama et al. (2003) published case series data suggesting clinical benefit in hepatocellular carcinoma and lung cancer patients receiving D-fraction adjunctively. No large-scale RCTs completed as of 2025.
Found In 1 Herb
3D Molecular Structure
D-fraction (Grifola frondosa proteoglucan)
Representative pattern: (C₆H₁₀O₅)ₙ
Live Research
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare practitioner before using any herbal product.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This content is for educational purposes only and is not a substitute for professional medical advice.
